Investors cheered the patent award, sending the stock up nearly 20% to $0.44 a share in New York.
The newly issued patent -- DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS -- covers devices for the detection of cells of interest, including circulating tumor cells (CTCs), that are shed into the bloodstream by solid tumors where an antibody, or mixture of antibodies, and any solid surface are used for cell capture, detection, and analysis.
The patent includes any biological sample type of interest and includes the use of single antibodies or cocktails of antibodies, Biocept said in a statement.
"The granting of this patent broadly expands Biocept's intellectual property estate for capturing and detecting cells of interest using antibodies, which combines nicely with our patented microchannel and cell staining platforms," said Lyle Arnold, Biocept's chief scientific officer.
"This allowed patent also interfaces very well with our other patented technologies that include a blood collection tube, and ctDNA analysis platforms for aiding patient treatment decisions."
The company said the device claims covered by the patent broadly apply to the use of antibodies for the capture and detection of target cells of interest on any solid surface. This includes CTCs, as well as any other cell of interest.
Capturing very rare cells
Combined with the company's patented microchannel and cell staining platform technologies, Biocept said it now has patented the capability to enable the capture of any cell of interest, including very rare cells, that may be present in blood and any other biological sample type.
"We continue to lead the way in innovation for liquid biopsy technology, and this latest patent demonstrates our leadership in creating new methodologies to identify potential cancer cells, or cells of any type for that matter,” said CEO Michael Nall.
“We are very proud of our innovations in the industry and look forward to sharing future applications for this patented technology to capture cellular targets in biological fluids, even when found in very small quantities."
Biocept, based in San Diego, has won more than 30 patents worldwide stemming from its liquid biopsy technology and commercial-testing platforms.
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham